NLNK NewLink Genetics Corporation

18.26
-1  -4%
Previous Close 19.02
Open 19.40
Price To book 4.28
Market Cap 533.48M
Shares 29,216,000
Volume 1,610,445
Short Ratio 5.64
Av. Daily Volume 582,800

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 pivotal China trial initiation announced April 21, 2017.
BGB-A317
Hodgkin lymphoma
Phase 2 poster presentation due at ASCO June 5, 2017. Abstract 3066.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase 2 interim analysis released at AACR meeting April 4, 2017.
Indoximod in combination with pembrolizumab
Melanoma - cancer
Phase 2 data due 2H 2017.
Indoximod + temozolomide
Glioblastoma multiforme cancer
Phase 2 data due 1H 2017.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Enrolling
Indoximod +Tergenpumatucel-L
Non-small cell lung cancer (NSCLC)
Phase 2 data due 2017.
Indoximod + taxane
Cancer - breast

Latest News

  1. NewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : April 21, 2017
  2. Should Gilead Sciences Acquire NewLink Genetics?
  3. NewLink Genetics Announces Presentation of Two Abstracts at ASCO
  4. NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : April 20, 2017
  5. Morgan Stanley Ups Incyte Target to $150
  6. The IDO-Inhibitor Race Is On to Improve Cancer Treatment
  7. NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017
  8. ETFs with exposure to NewLink Genetics Corp. : April 7, 2017
  9. NewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : April 7, 2017
  10. Why NewLink Genetics, Harmonic, and Innophos Holdings Slumped Today
  11. Why NewLink Genetics Shares Fell 10.3% Today
  12. NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm
  13. NewLink Genetics Corp. stock drops 28% on mid-stage results for melanoma drug
  14. Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary
  15. TrovaGene and NewLink Genetics Find Investors Optimistic About Products
  16. NewLink Genetics' shares surge after upgrade, seen as takeover target
  17. 5 Top Performing Stocks of the Best ETF of Q1
  18. Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront
  19. NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017